Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$47.98 - $54.4 $48,843 - $55,379
1,018 Added 18.05%
6,659 $361,000
Q4 2023

Feb 13, 2024

BUY
$48.48 - $57.85 $3,781 - $4,512
78 Added 1.4%
5,641 $289,000
Q3 2023

Nov 09, 2023

SELL
$57.89 - $64.73 $12,793 - $14,305
-221 Reduced 3.82%
5,563 $322,000
Q2 2023

Aug 10, 2023

BUY
$63.71 - $70.74 $79,892 - $88,707
1,254 Added 27.68%
5,784 $369,000
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $297,666 - $337,620
4,530 New
4,530 $313,000
Q1 2022

May 16, 2022

SELL
$61.48 - $73.72 $397,468 - $476,599
-6,465 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$53.63 - $62.52 $29,925 - $34,886
558 Added 9.45%
6,465 $403,000
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $44,377 - $51,982
750 Added 14.54%
5,907 $350,000
Q2 2020

Aug 13, 2020

SELL
$54.82 - $64.09 $42,814 - $50,054
-781 Reduced 13.15%
5,157 $303,000
Q1 2020

May 06, 2020

BUY
$46.4 - $67.43 $13,595 - $19,756
293 Added 5.19%
5,938 $366,000
Q4 2019

Jan 29, 2020

BUY
$49.21 - $64.19 $3,051 - $3,979
62 Added 1.11%
5,645 $362,000
Q3 2019

Nov 01, 2019

BUY
$42.77 - $50.71 $238,784 - $283,113
5,583 New
5,583 $283,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Angeles Investment Advisors, LLC Portfolio

Follow Angeles Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Angeles Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Angeles Investment Advisors, LLC with notifications on news.